Glucomanano, Glucomannane, Konjac Mannan.


Overview Information

Glucomannan is a dietary fiber. It is usually made from the root of the konjac plant. Glucommanan powder, capsules, and tablets are used as medicine.

Orally, glucomannan is used for constipation, weight loss, diabetes, high cholesterol, overactive thyroid (hyperthyroidism), high blood pressure, and stomach conditions called dumping syndrome and functional gastrointestinal disorder.

In foods, glucomannan is used as a thickener or gelling agent. Glucommanan flour and powder are used in food.

How does it work?

Glucomannan might work in the stomach and intestines by absorbing water to form a bulky fiber which treats constipation. It may also slow the absorption of sugar and cholesterol from the gut, helping to control sugar levels in diabetes, and reducing cholesterol levels.


Uses & Effectiveness?

Possibly Effective for

  • Constipation. Taking glucomannan by mouth can relieve constipation in adults. It might also reduce constipation in children, but results are inconsistent.
  • Diabetes. Taking glucomannan by mouth seems to reduce cholesterol, blood sugar levels, and blood pressure in people with diabetes.
  • High cholesterol. Taking glucomannan by mouth seems to improve cholesterol levels in people with high cholesterol.

Insufficient Evidence for

  • A stomach condition called dumping syndrome. Dumping syndrome occurs when food moves from the stomach to the intestines too quickly. This can cause the body to release a large amount of insulin, which can cause low blood sugar. Some early research shows that taking glucomannan by mouth helps prevent blood sugar from becoming too low after eating in people at risk for this condition. However, not all research agrees.
  • A stomach condition called functional gastrointestinal disorder. Early research shows that taking glucomannan does not improve stomach pain, cramping, or bloating in children with this condition.
  • High blood pressure. Early research shows that glucomannan might improve blood pressure in people with high blood pressure.
  • Overactive thyroid (hyperthyroidism). Early research shows that glucomannan plus methimazole and propranolol reduce thyroid hormone levels in people with too much thyroid hormone in the body.
  • Obesity. Some early research shows that taking glucomannan by mouth improves weight loss in overweight and obese adults and children. However, not all research agrees.
  • Other conditions.
More evidence is needed to rate glucomannan for these uses.

Side Effects

Side Effects & Safety

Glucomannan powder or flour is LIKELY SAFE when consumed as food. Glucomannan powder and capsules are POSSIBLY SAFE for most adults and children when used in medicinal amounts for up to 4 months. However, solid tablets containing glucomannan are POSSIBLY UNSAFE for adults and LIKELY UNSAFE for children. These can sometimes cause blockages of the throat or intestines.

Special Precautions & Warnings:

Pregnancy and breast-feeding: There is not enough reliable information about the safety of taking glucomannan if you are pregnant or breast-feeding. Stay on the safe side and avoid use.

Diabetes: Glucomannan may interfere with blood sugar control. Monitor blood sugar closely if you have diabetes and use glucomannan.

Surgery: Glucomannan might interfere with blood sugar control during and after surgery. Stop using glucomannan at least 2 weeks before a scheduled surgery.



Moderate Interaction

Be cautious with this combination

  • Medications for diabetes (Antidiabetes drugs) interacts with GLUCOMANNAN

    Glucomannan can decrease blood sugar in people with type 2 diabetes. Diabetes medications are also used to lower blood sugar. Taking glucomannan along with diabetes medications might cause your blood sugar to go too low. Monitor your blood sugar closely. The dose of your diabetes medication might need to be changed.<br/><br/> Some medications used for diabetes include glimepiride (Amaryl), glyburide (DiaBeta, Glynase PresTab, Micronase), insulin, pioglitazone (Actos), rosiglitazone (Avandia), chlorpropamide (Diabinese), glipizide (Glucotrol), tolbutamide (Orinase), and others.

  • Medications taken by mouth (Oral drugs) interacts with GLUCOMANNAN

    Glucomannan absorbs substances in the stomach and intestines. Taking glucomannan along with medications taken by mouth can decrease how much medicine your body absorbs, and decrease the effectiveness of your medication. To prevent this interaction, take glucomannan at least one hour after medications you take by mouth.



The following doses have been studied in scientific research:



  • For constipation: Glucomannan doses typically range from 2-4.5 grams daily, taken in divided doses.
  • For high cholesterol: Various glucomannan doses and dosage forms have been used, short-term (up to 12 weeks). These include eating biscuits containing 0.5-0.7 grams of glucomannan per 100 kcal, taking 2.4-3.9 grams of glucomannan supplements daily, eating bars containing 3.33 grams of glucomannan three times daily, or eating foods containing 5-10 grams of glucomannan daily.
  • For type 2 diabetes: Doses of about 3-4 grams of glucomannan have been used daily for up to 8 weeks. Eating biscuits containing 0.5-0.7 grams of glucomannan per 100 kcal has also been used for 3 weeks. A specific supplement providing 2.5-7.5 grams of glucomannan has also been used with meals.

  • For constipation: 100 mg/kg of glucomannan has been taken once or twice daily (up to a maximum of 5 grams daily) for up to 12 weeks.
  • For high cholesterol: Doses of 1 gram of glucomannan have been taken twice daily for 8 weeks in children 6 years of age and under. Dose of 1.5 grams of glucomannan have been taken twice daily for 8 weeks in children older than 6 years of age.

View References


  • Vita PM, Restelli A, Caspani P, et al. [Chronic use of glucomannan in the dietary treatment of severe obesity]. Minerva Med 1992;83:135-9. View abstract.
  • Acheampong, Y. B. Detection of bacterial spoilage in some fruit flavoured ultra-high temperature milks in Nigeria. Afr J Med Med Sci 1986;15(1-2):1-5. View abstract.
  • Alaoui-Ismaili, O., Robin, O., Rada, H., Dittmar, A., and Vernet-Maury, E. Basic emotions evoked by odorants: comparison between autonomic responses and self-evaluation. Physiol Behav. 1997;62(4):713-720. View abstract.
  • Ali, L., Perfetti, G., and Diachenko, G. Rapid method for the determination of coumarin, vanillin, and ethyl vanillin in vanilla extract by reversed-phase liquid chromatography with ultraviolet detection. J AOAC Int 2008;91(2):383-386. View abstract.
  • Aruoma, O. I. Dietary management of sickle cell anaemia with vanillin. Free Radic.Res Commun 1992;17(5):349-352. View abstract.
  • Ashkenazi, A. and Marks, L. E. Effect of endogenous attention on detection of weak gustatory and olfactory flavors. Percept.Psychophys. 2004;66(4):596-608. View abstract.
  • Atanasova, B., El Hage, W., Chabanet, C., Gaillard, P., Belzung, C., and Camus, V. Olfactory anhedonia and negative olfactory alliesthesia in depressed patients. Psychiatry Res 4-30-2010;176(2-3):190-196. View abstract.
  • Avila, M., Zougagh, M., Escarpa, A., and Rios, A. Fast single run of vanilla fingerprint markers on microfluidic-electrochemistry chip for confirmation of common frauds. Electrophoresis 2009;30(19):3413-3418. View abstract.
  • Bamforth, K. J., Jones, A. L., Roberts, R. C., and Coughtrie, M. W. Common food additives are potent inhibitors of human liver 17 alpha-ethinyloestradiol and dopamine sulphotransferases. Biochem.Pharmacol 11-17-1993;46(10):1713-1720. View abstract.
  • Bartocci, M., Winberg, J., Ruggiero, C., Bergqvist, L. L., Serra, G., and Lagercrantz, H. Activation of olfactory cortex in newborn infants after odor stimulation: a functional near-infrared spectroscopy study. Pediatr.Res 2000;48(1):18-23. View abstract.
  • Beaudry, F., Ross, A., and Vachon, P. Development of a LC-ESI/MS/MS assay for the quantification of vanillin using a simple off-line dansyl chloride derivatization reaction to enhance signal intensity. Biomed.Chromatogr. 2007;21(2):113-115. View abstract.
  • Becker, E., Hummel, T., Piel, E., Pauli, E., Kobal, G., and Hautzinger, M. Olfactory event-related potentials in psychosis-prone subjects. Int J Psychophysiol. 1993;15(1):51-58. View abstract.
  • Beckers, H. J., Coutinho, R. A., Jansen, J. T., and van Leeuwen, W. J. [Staphylococcal enterotoxicosis caused by consumption of sterilized vanilla custard]. Ned Tijdschr Geneeskd 5-10-1980;124(19):734-737. View abstract.
  • Bolles, R. C., Hayward, L., and Crandall, C. Conditioned taste preferences based on caloric density. J Exp.Psychol Anim Behav.Process 1981;7(1):59-69. View abstract.
  • Bouetard, A., Lefeuvre, P., Gigant, R., Bory, S., Pignal, M., Besse, P., and Grisoni, M. Evidence of transoceanic dispersion of the genus Vanilla based on plastid DNA phylogenetic analysis. Mol.Phylogenet.Evol. 2010;55(2):621-630. View abstract.
  • Brunschwig, C., Collard, F. X., Bianchini, J. P., and Raharivelomanana, P. Evaluation of chemical variability of cured vanilla beans (Vanilla tahitensis and Vanilla planifolia). Nat.Prod.Commun 2009;4(10):1393-1400. View abstract.
  • Brunton, P. A. and Hussain, A. The erosive effect of herbal tea on dental enamel. J Dent. 2001;29(8):517-520. View abstract.
  • Camps, N., Dominguez, A., Company, M., Perez, M., Pardos, J., Llobet, T., Usera, M. A., and Salleras, L. A foodborne outbreak of Salmonella infection due to overproduction of egg-containing foods for a festival. Epidemiol.Infect. 2005;133(5):817-822. View abstract.
  • Cerrutti, P. Alzamora S. Vanillin as an antimicrobial for producing shelf-stable strawberry puree. Journal of Food Science 1997;62(3):608.
  • Cheng, W. Y., Hsiang, C. Y., Bau, D. T., Chen, J. C., Shen, W. S., Li, C. C., Lo, H. Y., Wu, S. L., Chiang, S. Y., and Ho, T. Y. Microarray analysis of vanillin-regulated gene expression profile in human hepatocarcinoma cells. Pharmacol Res 2007;56(6):474-482. View abstract.
  • Cheryan, M. Deshpande S. Evaluation of vanillin assay for tannin analysis of dry beans. Journal of Food Science 1985;50(4):905.
  • Wood, R. J., Fernandez, M. L., Sharman, M. J., Silvestre, R., Greene, C. M., Zern, T. L., Shrestha, S., Judelson, D. A., Gomez, A. L., Kraemer, W. J., and Volek, J. S. Effects of a carbohydrate-restricted diet with and without supplemental soluble fiber on plasma low-density lipoprotein cholesterol and other clinical markers of cardiovascular risk. Metabolism 2007;56(1):58-67. View abstract.
  • Yoshida, M., Vanstone, C. A., Parsons, W. D., Zawistowski, J., and Jones, P. J. Effect of plant sterols and glucomannan on lipids in individuals with and without type II diabetes. Eur.J Clin Nutr. 2006;60(4):529-537. View abstract.
  • Zhang, M. Y., Huang, C. Y., Wang, X., Hong, J. R., and Peng, S. S. The effect of foods containing refined Konjac meal on human lipid metabolism. Biomed.Environ.Sci 1990;3(1):99-105. View abstract.
  • Arvill A, Bodin L. Effect of short-term ingestion of konjac glucomannan on serum cholesterol in healthy men. Am J Clin Nutr 1995;61:585-9. View abstract.
  • Brand-Miller JC, Atkinson FS, Gahler RJ, et al. Effects of PGX, a novel functional fibre, on acute and delayed postprandial glycaemia. Eur J Clin Nutr 2010;64(12):1488-93. View abstract.
  • Cairella M, Marchini GAD. [Evaluation of the action of glucomannan on metabolic parameters and on the sensation of satiation in overweight and obese patients]. [Article in Italian] Clin Ter 1995;146:269-74. View abstract.
  • Carabin IG, Lyon MR, Wood S, et al. Supplementation of the diet with the functional fiber PolyGlycoplex is well tolerated by healthy subjects in a clinical trial. Nutr J 2009;8:9. View abstract.
  • Chen HL, Sheu WH, Tai TS, et al. Konjac supplement alleviated hypercholesterolemia and hyperglycemia in type 2 diabetic subjects--a randomized double-blind trial. J Am Coll Nutr 2003;22:36-42. View abstract.
  • Chmielewska A, Horvath A, Dziechciarz P, Szajewska H. Glucomannan is not effective for the treatment of functional constipation in children: a double-blind, placebo-controlled, randomized trial. Clin Nutr 2011;30(4):462-8. View abstract.
  • Doi K, Matsuura M, Kawara A, Baba S. Treatment of diabetes with glucomannan (konjac mannan). Lancet 1979;1:987-8.
  • Doi K, Matsuura M, Kawara A, et al. Influence of dietary fiber (konjac mannan) on absorption of vitamin B12 and vitamin E (abstract). Tohoku J Exp Med 1983;141:677-81. View abstract.
  • Gallaher DD, Gallaher CM, Mahrt GJ, et al. A glucomannan and chitosan fiber supplement decreases plasma cholesterol and increases cholesterol excretion in overweight normocholesterolemic humans. J Am Coll Nutr 2002;21:428-33. View abstract.
  • Henry DA, Mitchell AS, Aylward J, et al. Glucomannan and risk of oesophageal obstruction. Br Med J 1986;292:591-2.
  • Horvath A, Dziechciarz P, Szajewska H. Glucomannan for abdominal pain-related functional gastrointestinal disorders in children: a randomized trial. World J Gastroenterol 2013;19(20):3062-8. View abstract.
  • Jenkins AL, Kacinik V, Lyon MR, Wolever TM. Reduction of postprandial glycemia by the novel viscous polysaccharide PGX, in a dose-dependent manner, independent of food form. J Am Coll Nutr 2010;29(2):92-8. View abstract.
  • Kaats GR, Bagchi D, Preuss HG. Konjac glucomannan dietary supplementation causes significant fat loss in compliant overweight adults. J Am Coll Nutr 2015; Online ahead of print. View abstract
  • Keithley JK, Swanson B, Mikolaitis SL, et al. Safety and efficacy of glucomannan for weight loss in overweight and moderately obese adults. J Obes 2013;2013:610908. View abstract.
  • Livieri C, Novazi F, Lorini R. [The use of highly purified glucomannan-based fibers in childhood obesity]. Pediatr Med Chir 1992;14:195-8. View abstract.
  • Lyon M, Wood S, Pelletier X, et al. Effects of a 3-month supplementation with a novel soluble highly viscous polysaccharide on anthropometry and blood lipids in nondieting overweight or obese adults. J Hum Nutr Diet 2011;24(4):351-9. View abstract.
  • Lyon MR, Reichert RG. The effect of a novel viscous polysaccharide along with lifestyle changes on short-term weight loss and associated risk factors in overweight and obese adults: an observational retrospective clinical program analysis. Altern Med Rev 2010;15(1):68-75. View abstract.
  • Marone PA, Lyon M, Gahler R, et al. Genotoxicity studies of PolyGlycoleX (PGX): a novel dietary fiber. Int J Toxicol 2009;28(4):318-31. View abstract.
  • Matulka RA, Lyon MR, Wood S, et al. The safety of PolyGlycopleX (PGX) as shown in a 90-day rodent feeding study. Nutr J 2009;8:1. View abstract.
  • Onakpoya I, Posadzki P, Ernst E. The efficacy of glucomannan supplementation in overweight and obesity: a systematic review and meta-analysis of randomized clinical trial. J Am Coll Nutr 2014;33(1):70-8. View abstract.
  • Passaretti S, Franzoni M, Comin U, et al. Action of glucomannans on complaints in patients affected with chronic constipation: a multicentric clinical evaluation. Ital J Gastroenterol 1991;23:421-5. View abstract.
  • Shima K, Tanaka A, Ikegami H, et al. Effect of dietary fiber, glucomannan, on absorption of sulfonylurea in man. Horm Metab Res 1983;15:1-3. View abstract.
  • Staiano A, Simeone D, Del Giudice E, et al. Effect of the dietary fiber glucomannan on chronic constipation in neurologically impaired children. J Pediatr 2000;136:41-5. View abstract.
  • Vido L, Facchin P, Antonello I, et al. Childhood obesity treatment: double blinded trial on dietary fibres (glucomannan) versus placebo. Padiatr Padol 1993;28:133-6. View abstract.
  • Choo, J. H., Rukayadi, Y., and Hwang, J. K. Inhibition of bacterial quorum sensing by vanilla extract. Lett.Appl.Microbiol 2006;42(6):637-641. View abstract.
  • Choochote, W., Chaithong, U., Kamsuk, K., Jitpakdi, A., Tippawangkosol, P., Tuetun, B., Champakaew, D., and Pitasawat, B. Repellent activity of selected essential oils against Aedes aegypti. Fitoterapia 2007;78(5):359-364. View abstract.
  • Cicchetti, E. and Chaintreau, A. Quantitation of the main constituents of vanilla by reverse phase HPLC and ultra-high-pressure-liquid-chromatography with UV detection: method validation and performance comparison. J Sep.Sci 2009;32(17):3043-3052. View abstract.
  • Cowden, J. M., Chisholm, D., O'Mahony, M., Lynch, D., Mawer, S. L., Spain, G. E., Ward, L., and Rowe, B. Two outbreaks of Salmonella enteritidis phage type 4 infection associated with the consumption of fresh shell-egg products. Epidemiol.Infect. 1989;103(1):47-52. View abstract.
  • De Montis, M. G., Grappi, S., Gambarana, C., Leggio, B., Nanni, G., Scheggi, S., and Tagliamonte, A. Sardinian alcohol-preferring rats show low 5-HT extraneuronal levels in the mPFC and no habituation in monoaminergic response to repeated ethanol consumption in the NAcS. Brain Res 4-23-2004;1006(1):18-27. View abstract.
  • de Tamsut, L. S. and Garcia, C. E. [Microbiological quality of vanilla ice cream manufactured in Caracas, Venezuela]. Arch Latinoam.Nutr. 1989;39(1):46-56. View abstract.
  • Debowska, R. and Podstolski, A. Properties of diphenolase from Vanilla planifolia (Andr.) shoot primordia cultured in vitro. J Agric Food Chem 2001;49(7):3432-3437. View abstract.
  • Decker, S., McConnaughey, S., and Page, T. L. Circadian regulation of insect olfactory learning. Proc.Natl.Acad.Sci U.S.A 10-2-2007;104(40):15905-15910. View abstract.
  • Deters, M., Knochenwefel, H., Lindhorst, D., Koal, T., Meyer, H. H., Hansel, W., Resch, K., and Kaever, V. Different curcuminoids inhibit T-lymphocyte proliferation independently of their radical scavenging activities. Pharm Res 2008;25(8):1822-1827. View abstract.
  • Dignum, M. J., Kerler, J., and Verpoorte, R. beta-Glucosidase and peroxidase stability in crude enzyme extracts from green beans of Vanilla planifolia Andrews. Phytochem.Anal. 2001;12(3):174-179. View abstract.
  • Durant, S. and Karran, P. Vanillins--a novel family of DNA-PK inhibitors. Nucleic Acids Res 10-1-2003;31(19):5501-5512. View abstract.
  • Eccles, R., Griffiths, D. H., Newton, C. G., and Tolley, N. S. The effects of D and L isomers of menthol upon nasal sensation of airflow. J Laryngol Otol 1988;102(6):506-508. View abstract.
  • Eccles, R., Jawad, M. S., and Morris, S. Olfactory and trigeminal thresholds and nasal resistance to airflow. Acta Otolaryngol. 1989;108(3-4):268-273. View abstract.
  • Eccles, R., Lancashire, B., and Tolley, N. S. Experimental studies on nasal sensation of airflow. Acta Otolaryngol. 1987;103(3-4):303-306. View abstract.
  • Estrada, Alvarado, I, Lomascolo, A., Navarro, D., Delattre, M., Asther, M., and Lesage-Meessen, L. Evidence of a new biotransformation pathway of p-coumaric acid into p-hydroxybenzaldehyde in Pycnoporus cinnabarinus. Appl.Microbiol Biotechnol 2001;57(5-6):725-730. View abstract.
  • Farthing, D., Sica, D., Abernathy, C., Fakhry, I., Roberts, J. D., Abraham, D. J., and Swerdlow, P. High-performance liquid chromatographic method for determination of vanillin and vanillic acid in human plasma, red blood cells and urine. J Chromatogr.B Biomed.Sci Appl. 4-16-1999;726(1-2):303-307. View abstract.
  • Fenton, P. A., Dobson, K. W., Eyre, A., and McKendrick, M. W. Unusually severe food poisoning from vanilla slices. J Hyg (Lond) 1984;93(2):377-380. View abstract.
  • Ferguson, J. E. and Beck, M. H. Contact sensitivity to vanilla in a lip salve. Contact Dermatitis 1995;33(5):352. View abstract.
  • Feron, V. J., Til, H. P., de Vrijer, F., Woutersen, R. A., Cassee, F. R., and van Bladeren, P. J. Aldehydes: occurrence, carcinogenic potential, mechanism of action and risk assessment. Mutat.Res 1991;259(3-4):363-385. View abstract.
  • Ferrante, S., Guerrero, S., and Alzamorat, S. M. Combined use of ultrasound and natural antimicrobials to inactivate Listeria monocytogenes in orange juice. J Food Prot. 2007;70(8):1850-1856. View abstract.
  • Vuksan V, Jenkins DJ, Spadafora P, et al. Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes. A randomized controlled metabolic trial. Diabetes Care 1999;22:913-9. View abstract.
  • Vuksan V, Sievenpiper JL, Owen R, et al. Beneficial effects of viscous dietary fiber from Konjac-mannan in subjects with the insulin resistance syndrome: results of a controlled metabolic trial. Diabetes Care 2000;23:9-14. View abstract.
  • Walsh DE, Yaghoubian V, Behforooz A. Effect of glucomannan on obese patients: a clinical study. Int J Obes 1984;8:289-93. View abstract.

Vitamins Survey

Have you ever purchased GLUCOMANNAN?

Did you or will you purchase this product in-store or online?

Where did you or where do you plan to purchase this product?

Where did you or where do you plan to purchase this product?

What factors influenced or will influence your purchase? (check all that apply)

Vitamins Survey

Where did you or where do you plan to purchase this product?

Do you buy vitamins online or instore?

What factors are most important to you? (check all that apply)

More Resources for GLUCOMANNAN

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
© Therapeutic Research Faculty 2018.